AU582221B2 - Process for producing natural heparan sulphate in substantially pure form,and their pharmaceutical use - Google Patents

Process for producing natural heparan sulphate in substantially pure form,and their pharmaceutical use

Info

Publication number
AU582221B2
AU582221B2 AU54727/86A AU5472786A AU582221B2 AU 582221 B2 AU582221 B2 AU 582221B2 AU 54727/86 A AU54727/86 A AU 54727/86A AU 5472786 A AU5472786 A AU 5472786A AU 582221 B2 AU582221 B2 AU 582221B2
Authority
AU
Australia
Prior art keywords
sulphate
substantially pure
pure form
heparan sulphate
producing natural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU54727/86A
Other languages
English (en)
Other versions
AU5472786A (en
Inventor
Luigi De Amrbosi
Rinaldo Del Bono
Gianni Ferrari
Piergiuseppe Pagella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mediolanum Farmaceutici SpA
Original Assignee
Mediolanum Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediolanum Farmaceutici SpA filed Critical Mediolanum Farmaceutici SpA
Publication of AU5472786A publication Critical patent/AU5472786A/en
Application granted granted Critical
Publication of AU582221B2 publication Critical patent/AU582221B2/en
Assigned to MEDIOLANUM FARMACEUTICI S.P.A. reassignment MEDIOLANUM FARMACEUTICI S.P.A. Request to Amend Deed and Register Assignors: MEDIOLANUM FARMACEUTICI S.R.L.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0066Isolation or extraction of proteoglycans from organs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/00272-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU54727/86A 1985-03-13 1986-03-13 Process for producing natural heparan sulphate in substantially pure form,and their pharmaceutical use Ceased AU582221B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT19885/85 1985-03-13
IT8519885A IT1208509B (it) 1985-03-13 1985-03-13 Processo per la produzione di eparan solfato e dermatan solfato naturali sostanzialmente puri eloro impiego farmaceutico.

Publications (2)

Publication Number Publication Date
AU5472786A AU5472786A (en) 1986-09-18
AU582221B2 true AU582221B2 (en) 1989-03-16

Family

ID=11162062

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54727/86A Ceased AU582221B2 (en) 1985-03-13 1986-03-13 Process for producing natural heparan sulphate in substantially pure form,and their pharmaceutical use

Country Status (20)

Country Link
US (1) US4783447A (US06589383-20030708-C00041.png)
EP (1) EP0199033B1 (US06589383-20030708-C00041.png)
JP (1) JPS61218601A (US06589383-20030708-C00041.png)
KR (1) KR910006809B1 (US06589383-20030708-C00041.png)
AT (1) ATE99702T1 (US06589383-20030708-C00041.png)
AU (1) AU582221B2 (US06589383-20030708-C00041.png)
CA (1) CA1286286C (US06589383-20030708-C00041.png)
DE (1) DE3689493T2 (US06589383-20030708-C00041.png)
DK (1) DK113886A (US06589383-20030708-C00041.png)
ES (1) ES8705894A1 (US06589383-20030708-C00041.png)
FI (1) FI82700C (US06589383-20030708-C00041.png)
GR (1) GR860677B (US06589383-20030708-C00041.png)
IN (1) IN163616B (US06589383-20030708-C00041.png)
IT (1) IT1208509B (US06589383-20030708-C00041.png)
NO (1) NO166187C (US06589383-20030708-C00041.png)
NZ (1) NZ215435A (US06589383-20030708-C00041.png)
PH (2) PH22370A (US06589383-20030708-C00041.png)
PT (1) PT82198B (US06589383-20030708-C00041.png)
YU (1) YU46303B (US06589383-20030708-C00041.png)
ZA (1) ZA861855B (US06589383-20030708-C00041.png)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1189085B (it) * 1986-03-25 1988-01-28 Mediolanum Farmaceutici Srl Processo per la preparazione di dermatan solfato ad alta purezza e composizioni farmaceutiche che lo contengono
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
DE3639561A1 (de) * 1986-11-20 1988-06-01 Baumann Hanno Verfahren zur herstellung von nicht-thrombogenen substraten
IT1232939B (it) * 1987-11-06 1992-03-10 Opocrin Spa Eparan solfato caratterizzato da elevata attivita' antitrombotica, elevata biodisponibilita', assenza di attivita' anticoagulante; suo processo di estrazione da organi e da tessuti e relative composizioni farmaceutiche
MC2098A1 (fr) * 1988-06-03 1991-02-15 Italfarmaco Spa Sels de glycosaminoglycanes,procedes pour leur preparation et compositions pharmaceutiques les contenant
EP0421508B1 (en) * 1989-10-04 1993-12-15 Akzo Nobel N.V. Sulphated glycosaminoglycuronan with antithrombotic activity
AU6872691A (en) * 1989-10-27 1991-05-31 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
IT1240615B (it) * 1990-04-03 1993-12-17 Mediolanum Farmaceutici Spa Impiego del dermatan solfato nella prevenzione e terapia dell'invecchiamento cerebrale e degli stati di deficit funzionale del sistema nervoso centrale
WO1991015217A1 (en) * 1990-04-06 1991-10-17 Washington University Anticoagulant oligosaccharides
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
FR2691066B1 (fr) * 1992-05-15 1995-06-09 Sanofi Elf Utilisation de glycosaminoglycanes exogenes, de leurs analogues ainsi que de leurs fragments, fractions et derives, pour la preparation de medicaments destines au traitement de thrombopenies.
IT1256236B (it) * 1992-12-23 1995-11-29 Mediolanum Farmaceutici Srl Oligosaccaridi aventi attivita' biologica e procedimento per la loro preparazione di glicosaminoglicani
CN1115182A (zh) * 1993-09-30 1996-01-17 生化学工业株式会社 抗血栓剂
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
IT1296581B1 (it) * 1997-11-28 1999-07-14 Istituto Scient Di Chimica E B Materiali polimerici non trombogenici e ad esaltata compatibilita' con fluidi e tessuti organici
CN1371391A (zh) * 1999-06-30 2002-09-25 汉密尔顿市医院研究发展有限公司 抑制凝血相关凝血因子的肝素成分
CN1473061A (zh) * 2000-09-08 2004-02-04 ���ܶ�����ҽԺ�о���չ���޹�˾ 抗血栓形成的组合物
CN107098989A (zh) * 2017-04-27 2017-08-29 甘肃省金羚集团药业有限公司 一种肝素钠的制备方法
CN114478832B (zh) * 2022-02-14 2023-03-03 河北常山生化药业股份有限公司 从肝素钠副产物中提纯四种多糖类产品的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2509384A (en) * 1983-03-08 1984-09-13 Opocrin S.P.A. Heparin degradation via ascorbic acid, cupric acetate and hydrogen peroxide
AU3053884A (en) * 1983-07-13 1985-01-17 Laboratori Baldacci Spa Heterogeneous oligosaccharides
AU3635384A (en) * 1983-12-05 1985-06-13 Sanofi Chitosan 6-sulfate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3179566A (en) * 1963-05-16 1965-04-20 Canada Packers Ltd Purification of heparin
JPS5318520B2 (US06589383-20030708-C00041.png) * 1972-07-05 1978-06-15
AR207237A1 (es) * 1974-02-25 1976-09-22 Thomas A Procedimiento para obtener extractos biologicos estables liofilizados solubles constituidos por complejos proteicos termorresistentes
US4243582A (en) * 1979-04-26 1981-01-06 Monsanto Company Novel glycoproteins from bovine cartilage
JPS58171403A (ja) * 1982-04-01 1983-10-08 Eisai Co Ltd ヘパラン硫酸の精製法
IT1189298B (it) * 1982-06-18 1988-02-04 Manetti & Roberts Italo Brit Procedimento per produrre i glicosa minoglicani dermatansolfato ed eparan-solfato sostanzialmente puri e loro impiego farmaceutico

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2509384A (en) * 1983-03-08 1984-09-13 Opocrin S.P.A. Heparin degradation via ascorbic acid, cupric acetate and hydrogen peroxide
AU3053884A (en) * 1983-07-13 1985-01-17 Laboratori Baldacci Spa Heterogeneous oligosaccharides
AU3635384A (en) * 1983-12-05 1985-06-13 Sanofi Chitosan 6-sulfate

Also Published As

Publication number Publication date
NZ215435A (en) 1989-01-06
ZA861855B (en) 1986-10-29
KR860007278A (ko) 1986-10-10
PT82198A (en) 1986-04-01
IT8519885A0 (it) 1985-03-13
EP0199033B1 (en) 1994-01-05
PH25136A (en) 1991-02-19
YU37586A (en) 1988-04-30
CA1286286C (en) 1991-07-16
FI861020A0 (fi) 1986-03-12
ATE99702T1 (de) 1994-01-15
JPH0238601B2 (US06589383-20030708-C00041.png) 1990-08-31
ES8705894A1 (es) 1987-05-16
NO166187C (no) 1991-06-12
FI82700B (fi) 1990-12-31
DK113886D0 (da) 1986-03-12
AU5472786A (en) 1986-09-18
DK113886A (da) 1986-09-14
EP0199033A3 (en) 1988-03-30
YU46303B (sh) 1993-05-28
PT82198B (pt) 1988-02-17
IT1208509B (it) 1989-07-10
KR910006809B1 (ko) 1991-09-02
US4783447A (en) 1988-11-08
ES552898A0 (es) 1987-05-16
NO166187B (no) 1991-03-04
PH22370A (en) 1988-08-12
FI861020A (fi) 1986-09-14
EP0199033A2 (en) 1986-10-29
JPS61218601A (ja) 1986-09-29
FI82700C (fi) 1991-04-10
NO860940L (no) 1986-09-15
GR860677B (en) 1986-07-14
DE3689493T2 (de) 1994-04-28
IN163616B (US06589383-20030708-C00041.png) 1988-10-15
DE3689493D1 (de) 1994-02-17

Similar Documents

Publication Publication Date Title
AU582221B2 (en) Process for producing natural heparan sulphate in substantially pure form,and their pharmaceutical use
CA1247033A (en) POLYSACCHARIDE POLYMER PRODUCED BY XANTHOMONAS
CA2067211A1 (en) Phospholipid- or lipid-linked glycosaminoglycan, process for producing the same and metastasis inhibitor
NZ333925A (en) Use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
AU1295200A (en) Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
CA2285383A1 (en) Glycosaminoglycans having high antithrombotic activity
ES8707967A1 (es) Un procedimiento para la preparacion de nuevos derivados de disacaridos o trisacaridos.
CA2133885A1 (en) Crystalline inclusion complex of diclofenac with beta-cyclodextrin
DE3866686D1 (de) Verwendung von polysulfatierten heparinen.
IT1189298B (it) Procedimento per produrre i glicosa minoglicani dermatansolfato ed eparan-solfato sostanzialmente puri e loro impiego farmaceutico
AU3742495A (en) Method of producing starch decomposition products
ATE332706T1 (de) Verwendung von hyaluronidase zur herstellung eines arzneimittels zur behandlung von entzündungen
AU5833694A (en) Oligosaccharides having biological activity and preparation of same from glycosaminoglycans
AU1192097A (en) 3-aminoethyl-n-amidino-2,5-dihydropyrrole derivatives having arginine mimetic properties
CA2348767A1 (en) Method for producing an antitumoral agent and antitumoral agent thus obtained
TAKEUCHI et al. Anticoagulant activities of acidic glycosaminoglycans cooperative action with AT III
HUT53912A (en) New process for producing disaccharid -octasulfate- aluminium-complexes and their hydrates
IT1178041B (it) Uso dell'acido ialuronico come veicolo per farmaci oftalmici e composizioni farmaceutiche contenenti questa sostanza
BG102009A (en) Method for the treatment of manic and two-pole disease